<div id="readability-page-1"><p>Ethic Inc. lessened its stake in shares of  Novo Nordisk A/S (NYSE:NVO - Free Report) by 25.0% in the third quarter, according to the company in its most recent 13F filing with the Securities &amp; Exchange Commission. The institutional investor  owned 69,154 shares of the company's stock after selling 22,990 shares during the period. Ethic Inc.'s holdings in Novo Nordisk A/S were worth $3,837,000 at the end of the most recent reporting period.</p><ul><li>Pfizer Adds to Its Big Bet on Weight Loss Drugs</li></ul><p>A number of other large investors have also added to or reduced their stakes in NVO. Jennison Associates LLC increased its holdings in shares of  Novo Nordisk A/S by 0.3% during the second quarter. Jennison Associates LLC now owns 18,885,343 shares of the company's stock valued at $1,303,466,000 after acquiring an additional 63,341 shares in the last quarter.  Loomis Sayles &amp; Co. L P boosted its stake in  Novo Nordisk A/S by 1.5% in the 2nd quarter. Loomis Sayles &amp; Co. L P now owns 12,576,031 shares of the company's stock worth $867,998,000 after purchasing an additional 187,789 shares in the last quarter.  Kingstone Capital Partners Texas LLC grew its position in  Novo Nordisk A/S by 301,443.6% during the 2nd quarter. Kingstone Capital Partners Texas LLC now owns 10,005,216 shares of the company's stock valued at $690,560,000 after purchasing an additional 10,001,898 shares during the last quarter.  Sustainable Growth Advisers LP increased its stake in  Novo Nordisk A/S by 11.7% during the 2nd quarter. Sustainable Growth Advisers LP now owns 6,192,636 shares of the company's stock valued at $427,416,000 after purchasing an additional 649,390 shares in the last quarter.  Finally, State Street Corp raised its holdings in  Novo Nordisk A/S by 0.8% in the second quarter. State Street Corp now owns 6,047,683 shares of the company's stock worth $418,231,000 after buying an additional 47,430 shares during the last quarter. Hedge funds and other institutional investors own  11.54% of the company's stock. </p><div><p><span></span><span>Get <strong>Novo Nordisk A/S</strong> alerts:</span></p></div><h2>Novo Nordisk A/S News Roundup</h2><p>Here are the key news stories impacting Novo Nordisk A/S this week:</p><ul>   <li><span>Positive Sentiment: </span>FDA approves Wegovy oral pill — a major commercial milestone that opens a new, non‑injectable patient segment and supports a planned U.S. launch in early 2026. This is the key bullish catalyst many investors celebrated. Read More.</li>    <li><span>Positive Sentiment: </span>First‑mover and efficacy edge vs. Lilly’s oral candidate — analysts note Novo may have a head start on oral GLP‑1 market share and trial data show strong weight‑loss results for oral Wegovy, which could help retention vs. competitors. Read More.</li>    <li><span>Neutral Sentiment: </span>Macro/ETF flow tailwinds — FDA nod to an oral GLP‑1 is expected to lift healthcare and obesity‑focused ETFs, bringing incremental investor demand even as company fundamentals are reassessed. Read More.</li>    <li><span>Neutral Sentiment: </span>Short‑term market reaction volatility — coverage notes big share swings after the approval (both big pops and pullbacks) as investors reprice growth expectations for 2026. Read More.</li>    <li><span>Negative Sentiment: </span>Price cuts in China and margin pressure — Novo has cut Wegovy prices in some Chinese provinces and trimmed prices ahead of generic threats, which alongside broader pricing moves could compress margins. Read More. Read More.</li>    <li><span>Negative Sentiment: </span>Margins and investor impatience — commentary warns oral product economics and broader price competition could erode profitability; some analysts flag the risk that oral Wegovy and aggressive pricing will pressure margins and investor patience. Read More.</li>    <li><span>Negative Sentiment: </span>Intense competition from Eli Lilly — Lilly’s tirzepatide franchise and its oral candidate keep competitive pressure high; market share and pricing battles remain key downside risks. Read More. Read More.</li> </ul><h2>Wall Street Analysts Forecast Growth</h2><ul><li>Golden Cross Alert: 3 Stocks With Major Upside Potential</li></ul><p>A number of equities research analysts have recently commented on NVO shares. Sanford C. Bernstein upgraded shares of Novo Nordisk A/S from a &#34;market perform&#34; rating to an &#34;outperform&#34; rating in a report on Tuesday, September 9th. Rothschild &amp; Co Redburn upgraded Novo Nordisk A/S from a &#34;neutral&#34; rating to a &#34;buy&#34; rating in a research note on Tuesday, September 16th. Hsbc Global Res lowered Novo Nordisk A/S from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a report on Monday, November 24th. Rothschild Redb upgraded Novo Nordisk A/S from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research note on Tuesday, September 16th. Finally, Argus  reaffirmed a &#34;hold&#34; rating on shares of Novo Nordisk A/S in a research report on Monday, December 8th. One research analyst  has rated the stock with a Strong Buy rating, six have given a Buy rating, eleven have given a Hold rating and four have assigned  a Sell rating to the stock. According to data from MarketBeat.com, Novo Nordisk A/S  has an average rating of &#34;Hold&#34; and a consensus price target of $53.33.</p><p><b>Read Our Latest Stock Analysis on Novo Nordisk A/S</b></p><h2>Novo Nordisk A/S Stock Down 0.5%</h2><ul><li>HIMS Has Been a Roller Coaster Ride. Should Investors Hop On?</li></ul><p>Novo Nordisk A/S stock opened at $51.19 on Wednesday. Novo Nordisk A/S has a one year low of $43.08 and a one year high of $93.80. The stock has a fifty day moving average of $49.19 and a 200 day moving average of $56.21. The company has a debt-to-equity ratio of 0.52, a quick ratio of 0.57 and a current ratio of 0.78. The stock has a market cap of $228.55 billion, a PE ratio of 14.88 and a beta of 0.67. </p><p>Novo Nordisk A/S (NYSE:NVO - Get Free Report) last released its quarterly earnings results on Wednesday, November 5th. The company reported $1.02 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.77 by $0.25. Novo Nordisk A/S had a return on equity of 73.50% and a net margin of 32.76%.The business had revenue of $11.79 billion during the quarter, compared to the consensus estimate of $11.98 billion.  As a group, sell-side analysts predict that  Novo Nordisk A/S will post 3.84 EPS for the current year. </p><h2>Novo Nordisk A/S Profile</h2> (Free Report)<p>Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, best known for its leadership in diabetes care and metabolic health. The company traces its roots to early Danish insulin production in the 1920s and was established in its current form through a 1989 merger of predecessor companies. Novo Nordisk develops, manufactures and markets pharmaceutical products and devices that address chronic and serious diseases, with a strong emphasis on long-term treatment and patient support.  </p><p>The company's core product portfolio centers on diabetes therapies, including a range of insulins and modern incretin-based treatments.</p><h2>See Also</h2><ul><li>Five stocks we like better than Novo Nordisk A/S</li><li>Do not delete, read immediately</li><li>The Crash Has Already Started (Most Just Don’t See It Yet)</li><li>ALERT: Drop these 5 stocks before January 2026!</li><li>[No Brainer Gold Play]: “Show me a better investment.”</li><li>INVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting Off</li></ul><p><strong>Want to see what other hedge funds are holding NVO?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPU5WTw"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Novo Nordisk A/S Right Now?</h2><p>Before you consider Novo Nordisk A/S, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Novo Nordisk A/S wasn't on the list.</p><p>While Novo Nordisk A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Ethic Inc. reduced its stake in Novo Nordisk A/S by 25% in Q3, selling 22,990 shares, leaving it with 69,154 shares valued at $3.84 million. Other investors, including Jennison Associates and Loomis Sayles, have also adjusted their holdings in Novo Nordisk. The company faces mixed sentiments due to FDA approvals and competitive pressures, with analysts providing varied ratings on its stock.</p>

Ethic Inc. Sells 22,990 Shares of Novo Nordisk A/S $NVO